| Features |
| |
| For reliable purification of viral RNA and DNA* from cell-free biological fluids |
• Reliable and reproducible isolation of viral RNA and DNA* – free of impurities
• Safe and well-established procedure
• Proven for a large variety of viruses including influenza viruses, HCV, HIV,
Bird Flu Virus, Blue Tongue Virus
• Carrier RNA included for highest sensitivity in downstream applications
• Fast and convenient protocol – viral RNA and DNA* within only 30 min
• Also available for QIAcube® (please see "Ordering information" and contact Technical Service
at techbio@mn-net.com for more information). |
| |
|
| Technology |
Silica-membrane technology |
| Format |
Mini spin columns |
| Sample material |
< 150 µL serum, plasma, cell-free biological fluids
|
| Fragment size |
100 bp–approx. 50 kbp
|
| Elution volume |
50 µL |
| Preparation time |
30 min/4–6 preps |
| Binding capacity |
40 µg |
| |
| Applications** |
| |
• Viral RNA from 150 μL serum, plasma, cell-free biological fluids
• HCV, HBV, HAV, HIV, HSV, HPV, VZV, EBV, parvovirus B19, H5N1, H1N1
• Support protocol for parallel isolation of viral RNA and DNA*
• Typical downstream applications: RT-PCR, enzymatic reactions |
| |
* For parallel isolation of viral RNA and DNA use of Proteinase K required (not included in the kit),
see "Ordering information"
** Kits to be used for research purposes only |
|
| |
|
|
Ordering information
| Product |
Preps
|
Specification |
REF |
| NucleoSpin® RNA Virus |
10
|
NucleoSpin® RNA Virus Columns with Collection Tubes, Collection Tubes (2 mL), buffers, Carrier RNA |
740956.10 |
| |
50
|
as above |
740956.50 |
| |
250
|
as above |
740956.250 |
| |
|
|
|
| |
240
|
Kit for use on QIAcube®*
NucleoSpin® RNA Virus Columns, buffers, Carrier RNA |
740956.240C |
| Product accessories |
Pack of
|
Specification |
REF |
| Proteinase K |
100 mg
|
|
740506 |
* NucleoSpin® kits on QIAcube®: The usage of NucleoSpin® kits on the QIAcube® is at your own liability.
MACHEREY-NAGEL is not responsible for loss of warranty claims or other consequences. |
|
